These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3093667)

  • 1. Relative bioavailability of a new transdermal nitroglycerin delivery system.
    Noonan PK; Gonzalez MA; Ruggirello D; Tomlinson J; Babcock-Atkinson E; Ray M; Golub A; Cohen A
    J Pharm Sci; 1986 Jul; 75(7):688-91. PubMed ID: 3093667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique.
    Sun JX; Piraino AJ; Morgan JM; Joshi JC; Cipriano A; Chan K; Redalieu E
    J Clin Pharmacol; 1995 Apr; 35(4):390-7. PubMed ID: 7650229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical considerations of transdermal nitroglycerin delivery: the various approaches.
    Chien YW
    Am Heart J; 1984 Jul; 108(1):207-16. PubMed ID: 6428207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative evaluation of two transdermal nitroglycerin delivery systems: Nitro-Dur versus Transderm-Nitro. The Collaborative Investigation Group.
    Clin Ther; 1991; 13(5):545-9. PubMed ID: 1799911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS).
    Imhof PR; Vuillemin T; Gérardin A; Racine A; Müller P; Follath F
    Eur J Clin Pharmacol; 1984; 27(1):7-12. PubMed ID: 6436032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.
    Shaw JE
    Am Heart J; 1984 Jul; 108(1):217-23. PubMed ID: 6428208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitroglycerin concentration in plasma: comparison between transdermal therapeutic system and ointment.
    Chu LC; Gale RM; Schmitt LG; Shaw JE
    Angiology; 1984 Sep; 35(9):545-52. PubMed ID: 6435484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure.
    Armstrong PW
    J Am Coll Cardiol; 1987 Feb; 9(2):420-5. PubMed ID: 3100600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of two spray formulations of nitroglycerin.
    Sanders SW; Michaelis K; Maurette JM; Jaeger H
    J Pharm Sci; 1986 Mar; 75(3):244-6. PubMed ID: 3084758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal nitroglycerin systems: methods for comparison.
    Harrison LI; Riedel DJ
    Clin Ther; 1991; 13(3):361-7. PubMed ID: 1954637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dose and ointment application technique on nitroglycerin plasma concentrations.
    Iafrate RP; Yost RL; Curry SH; Gotz VP; Caranasos GJ
    Pharmacotherapy; 1983; 3(2 Pt 1):118-24. PubMed ID: 6406987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incomplete and delayed bioavailability of sublingual nitroglycerin.
    Noonan PK; Benet LZ
    Am J Cardiol; 1985 Jan; 55(1):184-7. PubMed ID: 3917598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a new transdermal nitroglycerin adhesive patch formulation.
    Riedel DJ; Wick KA; Hawkinson RW; Kolars CA; Crowley JK; Armstrong KE; Chang SF; Harrison LI; de Dennis SR
    Clin Ther; 1989; 11(2):225-31. PubMed ID: 2500248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers.
    Gerardin A; Gaudry D; Moppert J; Theobald W; Fankhauser P
    Arzneimittelforschung; 1985; 35(2):530-2. PubMed ID: 3922382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variational analysis of the transdermal delivery rate from two prototypical ethanol-water nitroglycerin TTS devices and Transderm-Nitro 10 in the normal population.
    Kochak GM; Berner B; Leal M; Sambol NC
    J Pharmacokinet Biopharm; 1992 Oct; 20(5):443-59. PubMed ID: 1287196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.
    Williams RL; Thakker KM; John V; Lin ET; Liang-Gee W; Benet LZ
    Pharm Res; 1991 Jun; 8(6):744-9. PubMed ID: 1905809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the method of application on pharmacokinetics of nitroglycerin from ointment in humans.
    Sved S; McLean WM; McGilveray IJ
    J Pharm Sci; 1981 Dec; 70(12):1368-9. PubMed ID: 6798193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute bioavailability of glyceryl trinitrate from a transdermal system, assessed by digital plethysmography.
    Isenschmid M; Müller M; Bührer M; Vorkauf H; Bircher J
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):345-51. PubMed ID: 3928505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved skin adherence and patient acceptance in a new transdermal nitroglycerin delivery system.
    Hougham AJ; Hawkinson RW; Crowley JK; Wilson RR; Glode JE; Hilty RW; Hughes SO; Koeppl CG; Kovaric TR; Wyskoarko NP
    Clin Ther; 1989; 11(1):23-31. PubMed ID: 2497985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system.
    Auclair B; Sirois G; Ngoc AH; Ducharme MP
    Ther Drug Monit; 1998 Dec; 20(6):607-11. PubMed ID: 9853974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.